Myelodysplastic Syndrome Treatment Market Analysis

In myelodysplastic syndrome (MDS), some of the cells from bone marrow are abnormal and have problems making new blood cells. Moreover, increasing possibility of MDS to further progress into rapidly growing cancer of bone marrow cells called acute myeloid leukemia (AML), leads to increasing efforts by key players to develop highly effective therapies for MDS treatment. Moreover, awareness about the disease and its symptoms with advanced methods and techniques for early diagnosis and treatment for various forms of MDS is expected to drive the market growth over the forecast period. Increased understanding of the pathology of the syndrome is directing the research towards developing more specialized and symptom based treatments with effective costs, so that MDS patients can avail these benefits.

Global myelodysplastic syndrome (MDS) treatment market is estimated to be valued at US$ 3,265.6 million in 2022 and is expected to exhibit a CAGR of 9.3% during the forecast period (2022-2030).

Figure 1. Global Myelodysplastic Syndrome (MDS) Treatment Market Share (%), by Distribution Channel, 2022

Government organizations and drug manufacturing companies are focusing on spreading awareness about the myelodysplastic syndrome (MDS) disease, which is expected to drive the myelodysplastic syndrome (MDS) treatment market growth.

Government organizations and drug manufacturing companies are focusing on spreading awareness about the myelodysplastic syndrome (MDS) disease by providing funding for research and development of drugs used in the treatment of myelodysplastic syndrome (MDS) and conducting awareness programs about the myelodysplastic syndrome (MDS) disease. For instance, in October 2018, Grupo Biotoscana, a Latin American based biopharmaceutical company conducted a campaign to honor Myelodysplastic Syndrome World Awareness Day, which is celebrated on 25th October. GBT Grupo Biotoscana launched a campaign to raise awareness and educate about the disease.

Myelodysplastic Syndrome Treatment Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 3,265.6 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	9.3%	2030 Value Projection:	US$ 6,635.3 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Drug: Lenalidomide, Decitabine, Azacitidine, Phase 3 Drugs By Route Of Administration: Injection, Oral By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:	Celgene Corporation, Otsuka Pharmaceutical Co., Ltd. Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma, Inc., Aprea Therapeutics, FibroGen Inc., Onconova Therapeutics Inc., and Geron.
Growth Drivers:	Government organizations and drug manufacturing companies are focusing on spreading awareness about the myelodysplastic syndrome (MDS) disease Increasing regulatory approval of drugs for treating Myelodysplastic Syndrome (MDS)
Restraints & Challenges:	High cost of treatment for Myelodysplastic Syndrome (MDS)

Figure 2. Global Myelodysplastic Syndrome (MDS) Treatment Market Share (%), by Region, 2022

Increasing regulatory approval of drugs for treating Myelodysplastic Syndrome (MDS) is expected to be a driving factor contributing to growth of the global myelodysplastic syndrome treatment market over the forecast period.

Increasing regulatory approval for the drugs used in the treatment of Myelodysplastic Syndrome (MDS) treatment is expected to drive the market growth over the forecast period. For instance, in November 2018, Lupin received the U.S. Food and Drug Administration approval for its Decitabine for Injection, 50 mg/vial, single-dose vial, a generic version of Otsuka Pharmaceutical Co. Ltd.'s Dacogen for Injection, 50 mg/vial, single-dose vial. Lupin’s generic version is indicated for the treatment of patients with myelodysplastic syndromes (MDS), which includes previously treated and untreated, de novo, and secondary MDS of all French-American-British subtypes.

Moreover, in July 2020, the U.S. Food and Drug Administration approved Inqovi (decitabine and cedazuridine) tablets for treatment of adult patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). This represents an important advancement in treatment options for patients with myelodysplastic syndrome (MDS), a type of blood cancer, who previously used to receive intravenous therapy.

Global Myelodysplastic Syndrome (MDS) Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways: by directly affecting production and demand of drugs or medical devices, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, are facing problems with regards to the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a negative impact on the global myelodysplastic syndrome (MDS) treatment market, owing to the decreased research and development activities for the drugs used in Myelodysplastic Syndrome (MDS) treatment. For instance, in April 2020, according to the data published by the National Center for Biotechnology information, with increasing cases of infection with 2019-nCoV, several studies have proposed that human-to-human transmission is a probable route for the COVID-19 outbreak. The research and development activities for the drugs to treat coronavirus infection were on priority by key players in market. Key players in market were focusing on the highlights antiviral strategies involving small molecules and biologics targeting complex molecular interactions involved in coronavirus infection and replication. Considering the potential threat of a pandemic, scientists and physicians have been racing to understand this new virus and the pathophysiology of this disease to uncover possible treatment regimens and discover effective therapeutic agents and vaccines. Thus, the research and development activities for the treating Myelodysplastic Syndrome were slowed down.

Global Myelodysplastic Syndrome (MDS) Treatment Market: Key Developments

In July 21 2022, Karyopharm Therapeutics, a biotech company, received   new regulatory designations for eltanexor, a novel oral, and Selective Inhibitor of Nuclear Export (SINE) investigational compound being studied for the treatment of myelodysplastic syndromes (MDS). the U.S. Food and Drug Administration (FDA) had granted fast track designation for the development program of eltanexor as monotherapy for the treatment of patients with relapsed or refractory intermediate, high-, or very high-risk MDS. The European Commission (EC) adopted the Committee for Orphan Medicinal Products (COMP) opinion to designate eltanexor as an orphan medicinal product for the treatment of MDS in the European Union (EU). Karyopharm also received orphan drug designation from the Food and Drug Administration in January 2022.

Global Myelodysplastic Syndrome (MDS) Treatment Market: Restraint

The major factors that hinder growth of the global myelodysplastic syndrome (MDS) treatment market include high cost of treatment for Myelodysplastic Syndrome (MDS). For instance, in January 2018, according to the National Center for Biotechnology Information, myelodysplastic syndromes (MDS) encompass a range of myeloid neoplasms characterized by a defect in haematopoietic stem cell maturation, resulting in peripheral cytopenias. As a major consequence, most MDS patients become anemic, so as to require red blood cell transfusions. From Medline and Embase, 742 studies were identified, of which 17 were considered eligible. Total medical costs per patient/year range from US$ 9,840 to US$ 19,811 for the transient ischaemic attack (TI) condition and from US$ 29,608 to US$ 51,066 in Myelodysplastic Syndrome (MDS).

Key Players

Major players operating in the global myelodysplastic syndrome (MDS) treatment market include Celgene Corporation, Otsuka Pharmaceutical Co., Ltd. Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma, Inc., Aprea Therapeutics, FibroGen Inc., Onconova Therapeutics Inc., and Geron.